{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:27:41Z","timestamp":1738819661660,"version":"3.37.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Council of Canada Industrial Research Assistance Program","award":["953967"],"award-info":[{"award-number":["953967"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Since the emergence of SARS-CoV-2 and the COVID-19 pandemic, a wide range of treatment options have been evaluated in preclinical studies and clinical trials, with several being approved for use in humans. Immunomodulatory drugs have shown success in dampening the deleterious inflammatory response seen in severe COVID-19 patients, but there remains an urgent need for development of additional therapeutic options for COVID-19 treatment. A potential drug target is the CCR5-CCL5 axis, and blocking this pathway may protect against severe disease. Here we evaluated whether OB-002, an analog of human CCL5 and a potent antagonist of CCR5, provides therapeutic benefit in SARS-CoV-2 infected Syrian hamsters. Daily treatment with OB-002 altered immune gene transcription in the lungs, and reduced pathology following infection, but did not prevent weight loss or viral replication in the lungs of infected animals, even in combination with the antiviral drug remdesivir. Our data suggest that targeting the CCR5-CCL5 pathway in SARS-CoV-2 infection in hamsters is insufficient to significantly impact disease development in this model.<\/jats:p>","DOI":"10.1371\/journal.pone.0316952","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:36:37Z","timestamp":1738780597000},"page":"e0316952","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection"],"prefix":"10.1371","volume":"20","author":[{"given":"Bryce M.","family":"Warner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9131-2602","authenticated-orcid":true,"given":"Robert","family":"Vendramelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-4710","authenticated-orcid":true,"given":"Amrit S.","family":"Boese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Audet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikesh","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Meilleur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Glowach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnie","family":"Willman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thang","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estella","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Kosak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Dhanidina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarret","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Korczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carissa","family":"Embury-Hyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-7493","authenticated-orcid":true,"given":"Darwyn","family":"Kobasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"9","key":"pone.0316952.ref001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"OJ Watson","year":"2022","journal-title":"The Lancet Infectious Diseases"},{"issue":"6","key":"pone.0316952.ref002","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"A Jayk Bernal","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"pone.0316952.ref003","doi-asserted-by":"crossref","first-page":"n2697","DOI":"10.1136\/bmj.n2697","article-title":"Covid-19: UK becomes first country to authorise antiviral molnupiravir","volume":"375","author":"E. Mahase","year":"2021","journal-title":"BMJ"},{"key":"pone.0316952.ref004","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s Paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"E. Mahase","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"pone.0316952.ref005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis.","volume":"54","author":"W Wen","year":"2022","journal-title":"Annals of medicine"},{"issue":"1","key":"pone.0316952.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40001-021-00626-3","article-title":"Potential therapeutic options for COVID-19: an update on current evidence","volume":"27","author":"Z Niknam","year":"2022","journal-title":"European Journal of Medical Research"},{"issue":"2","key":"pone.0316952.ref007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(21)00440-9","article-title":"Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.","volume":"10","author":"A Mazeraud","year":"2022","journal-title":"The Lancet Respiratory Medicine"},{"key":"pone.0316952.ref008","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of COVID-19.","volume":"386","author":"MJ Levin","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"pone.0316952.ref009","doi-asserted-by":"crossref","first-page":"n2860","DOI":"10.1136\/bmj.n2860","article-title":"Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness","volume":"375","author":"E. Mahase","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"pone.0316952.ref010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.","volume":"27","author":"A Cortegiani","year":"2021","journal-title":"Pulmonology"},{"key":"pone.0316952.ref011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"TR Group","year":"2021","journal-title":"The New England journal of medicine"},{"issue":"8","key":"pone.0316952.ref012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19.","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0316952.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-023-01973-9","article-title":"An overview on the treatments and prevention against COVID-19","volume":"20","author":"Y Panahi","year":"2023","journal-title":"Virology Journal"},{"issue":"2","key":"pone.0316952.ref014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/08971900211048139","article-title":"COVID-19: a review of potential treatments (corticosteroids, remdesivir, tocilizumab, bamlanivimab\/etesevimab, and casirivimab\/imdevimab) and pharmacological considerations.","volume":"36","author":"S Nhean","year":"2023","journal-title":"Journal of pharmacy practice"},{"issue":"24","key":"pone.0316952.ref015","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2023.9925","article-title":"FDA grants full approval to paxlovid, COVID-19 antiviral treatment","volume":"329","author":"E. Harris","year":"2023","journal-title":"Jama"},{"issue":"1","key":"pone.0316952.ref016","article-title":"Remdesivir for the treatment of COVID\u201019.","author":"F Grundeis","year":"2023","journal-title":"Cochrane Database of Systematic Reviews."},{"issue":"4","key":"pone.0316952.ref017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40265-022-01684-5","article-title":"Molnupiravir: first approval.","volume":"82","author":"YY Syed","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"pone.0316952.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and Immunotherapeutics.","volume":"5","author":"L Yang","year":"2020","journal-title":"Signal transduction and targeted therapy."},{"issue":"6585","key":"pone.0316952.ref019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The immunology and immunopathology of COVID-19","volume":"375","author":"M Merad","year":"2022","journal-title":"Science"},{"issue":"9","key":"pone.0316952.ref020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"AC Kalil","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"pone.0316952.ref021","doi-asserted-by":"crossref","first-page":"e1010547","DOI":"10.1371\/journal.ppat.1010547","article-title":"Rationale of using the dual chemokine receptor CCR2\/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.","volume":"18","author":"DC Files","year":"2022","journal-title":"PLoS pathogens."},{"issue":"6","key":"pone.0316952.ref022","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/aid.2021.0010","article-title":"Evaluation of the safety, acceptability, and pharmacokinetic profile of a gel formulation of OB-002 in healthy volunteers","volume":"37","author":"IM McGowan","year":"2021","journal-title":"AIDS Research and Human Retroviruses"},{"key":"pone.0316952.ref023","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"issue":"1","key":"pone.0316952.ref024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1385\/MB:16:1:23","article-title":"Recombinant protein expression in Pichia pastoris","volume":"16","author":"JM Cregg","year":"2000","journal-title":"Molecular biotechnology"},{"key":"pone.0316952.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2015.10.011","article-title":"A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris","volume":"119","author":"F Cerini","year":"2016","journal-title":"Protein expression and purification"},{"issue":"8","key":"pone.0316952.ref026","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1089\/aid.2016.0199","article-title":"Stability of 5P12-RANTES, a candidate rectal microbicide, in human rectal lavage","volume":"33","author":"F Cerini","year":"2017","journal-title":"AIDS research and human retroviruses"},{"key":"pone.0316952.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.03.001","article-title":"Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention","volume":"301","author":"B Yavuz","year":"2019","journal-title":"Journal of Controlled Release"},{"issue":"10","key":"pone.0316952.ref028","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1086\/598685","article-title":"Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge","volume":"199","author":"RS Veazey","year":"2009","journal-title":"The Journal of infectious diseases"},{"issue":"12","key":"pone.0316952.ref029","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","article-title":"Targeting CCL5 in inflammation","volume":"17","author":"RE Marques","year":"2013","journal-title":"Expert opinion on therapeutic targets"},{"issue":"5","key":"pone.0316952.ref030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/vaccines9050436","article-title":"Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm","volume":"9","author":"AA Rabaan","year":"2021","journal-title":"Vaccines"},{"key":"pone.0316952.ref031","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3389\/fcell.2020.00677","article-title":"Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm?","volume":"8","author":"L Lu","year":"2020","journal-title":"Frontiers in cell and developmental biology"},{"key":"pone.0316952.ref032","article-title":"Disruption of the CCL5\/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19.","author":"BK Patterson","year":"2020","journal-title":"MedRxiv"},{"issue":"12","key":"pone.0316952.ref033","doi-asserted-by":"crossref","first-page":"103530","DOI":"10.1016\/j.isci.2021.103530","article-title":"Host parameters and mode of infection influence outcome in SARS-CoV-2-infected hamsters.","volume":"24","author":"BD Griffin","year":"2021","journal-title":"Iscience"},{"issue":"3","key":"pone.0316952.ref034","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"LJ Reed","year":"1938","journal-title":"American journal of epidemiology"},{"issue":"1\u20132","key":"pone.0316952.ref035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2011.02.004","article-title":"Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus).","volume":"368","author":"M Zivcec","year":"2011","journal-title":"Journal of immunological methods"},{"key":"pone.0316952.ref036","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/B978-0-12-380920-9.00034-1","volume-title":"The Experimental Use of Syrian Hamsters. The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents.","author":"H Valentine","year":"2012"},{"issue":"2","key":"pone.0316952.ref037","first-page":"238","article-title":"Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069\/ACTG A5305).","volume":"215","author":"RM Gulick","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0316952.ref038","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QAD.0000000000002038","article-title":"The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM","volume":"33","author":"I McGowan","year":"2019","journal-title":"AIDS"},{"issue":"4","key":"pone.0316952.ref039","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/aid.2021.0096","article-title":"A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).","volume":"38","author":"IM McGowan","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"pone.0316952.ref040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"RM Gulick","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0316952.ref041","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3182a7a97a","article-title":"Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients.","volume":"65","author":"RM Gulick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0316952.ref042","doi-asserted-by":"crossref","first-page":"104902","DOI":"10.1016\/j.antiviral.2020.104902","article-title":"The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro","volume":"182","author":"M Okamoto","year":"2020","journal-title":"Antiviral research"},{"key":"pone.0316952.ref043","author":"ClinicalTrials.gov [Internet]","year":"2000"},{"key":"pone.0316952.ref044","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"key":"pone.0316952.ref045","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"key":"pone.0316952.ref046","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"key":"pone.0316952.ref047","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"key":"pone.0316952.ref048","author":"ClinicalTrials.gov [Internet].","year":"2000"},{"issue":"2","key":"pone.0316952.ref049","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bjc.2014.572","article-title":"The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer","volume":"112","author":"ST Ward","year":"2015","journal-title":"British journal of cancer"},{"issue":"2","key":"pone.0316952.ref050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrneurol.2015.248","article-title":"CCR5 blockade for neuroinflammatory diseases\u2014beyond control of HIV","volume":"12","author":"G Martin-Blondel","year":"2016","journal-title":"Nature Reviews Neurology"},{"issue":"643","key":"pone.0316952.ref051","doi-asserted-by":"crossref","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"A Sch\u00e4fer","year":"2022","journal-title":"Science Translational Medicine"},{"key":"pone.0316952.ref052","doi-asserted-by":"crossref","first-page":"105331","DOI":"10.1016\/j.antiviral.2022.105331","article-title":"Remdesivir efficacy against yellow fever in a hamster model","volume":"203","author":"JG Julander","year":"2022","journal-title":"Antiviral Research"},{"issue":"2","key":"pone.0316952.ref053","doi-asserted-by":"crossref","first-page":"e03705","DOI":"10.1128\/mbio.03705-21","article-title":"The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication in vitro and decreases viral titers and disease progression in Syrian hamsters.","volume":"13","author":"IL Shytaj","year":"2022","journal-title":"Mbio"},{"issue":"1","key":"pone.0316952.ref054","first-page":"1","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"RM Cox","year":"2021","journal-title":"Nature communications"},{"issue":"19","key":"pone.0316952.ref055","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19","volume":"383","author":"JH Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"10236","key":"pone.0316952.ref056","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(20)31023-0","article-title":"Remdesivir for COVID-19: challenges of underpowered studies","volume":"395","author":"JD Norrie","year":"2020","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:36:57Z","timestamp":1738780617000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316952"}},"subtitle":[],"editor":[{"given":"Elisabetta","family":"Pilotti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316952","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}